Literature DB >> 31090233

The impact of postsynaptic density 95 blocking peptide (Tat-NR2B9c) and an iNOS inhibitor (1400W) on proteomic profile of the hippocampus in C57BL/6J mouse model of kainate-induced epileptogenesis.

Karen Tse1,2, Dean Hammond3, Deborah Simpson4, Robert J Beynon4, Edward Beamer1, Michael Tymianski5, Michael W Salter5, Graeme J Sills2, Thimmasettappa Thippeswamy1.   

Abstract

Antiepileptogenic agents that prevent the development of epilepsy following a brain insult remain the holy grail of epilepsy therapeutics. We have employed a label-free proteomic approach that allows quantification of large numbers of brain-expressed proteins in a single analysis in the mouse (male C57BL/6J) kainate (KA) model of epileptogenesis. In addition, we have incorporated two putative antiepileptogenic drugs, postsynaptic density protein-95 blocking peptide (PSD95BP or Tat-NR2B9c) and a highly selective inducible nitric oxide synthase inhibitor, 1400W, to give an insight into how such agents might ameliorate epileptogenesis. The test drugs were administered after the induction of status epilepticus (SE) and the animals were euthanized at 7 days, their hippocampi removed, and subjected to LC-MS/MS analysis. A total of 2,579 proteins were identified; their normalized abundance was compared between treatment groups using ANOVA, with correction for multiple testing by false discovery rate. Significantly altered proteins were subjected to gene ontology and KEGG pathway enrichment analyses. KA-induced SE was most robustly associated with an alteration in the abundance of proteins involved in neuroinflammation, including heat shock protein beta-1 (HSP27), glial fibrillary acidic protein, and CD44 antigen. Treatment with PSD95BP or 1400W moderated the abundance of several of these proteins plus that of secretogranin and Src substrate cortactin. Pathway analysis identified the glutamatergic synapse as a key target for both drugs. Our observations require validation in a larger-scale investigation, with candidate proteins explored in more detail. Nevertheless, this study has identified several mechanisms by which epilepsy might develop and several targets for novel drug development. OPEN PRACTICES: This article has been awarded Open Data. All materials and data are publicly accessible as supporting information. Learn more about the Open Practices badges from the Center for Open Science: https://osf.io/tvyxz/wiki.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  disease modification; glutamatergic synapse; inducible nitric oxide synthase (iNOS); neuroinflammation; postsynaptic density

Mesh:

Substances:

Year:  2019        PMID: 31090233      PMCID: PMC6752963          DOI: 10.1002/jnr.24441

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  80 in total

Review 1.  NMDA receptor regulation by Src kinase signalling in excitatory synaptic transmission and plasticity.

Authors:  D W Ali; M W Salter
Journal:  Curr Opin Neurobiol       Date:  2001-06       Impact factor: 6.627

2.  Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions.

Authors:  Michelle Aarts; Yitao Liu; Lidong Liu; Shintaro Besshoh; Mark Arundine; James W Gurd; Yu-Tian Wang; Michael W Salter; Michael Tymianski
Journal:  Science       Date:  2002-10-25       Impact factor: 47.728

3.  Q/R editing of the rat GluR5 and GluR6 kainate receptors in vivo and in vitro: evidence for independent developmental, pathological and cellular regulation.

Authors:  A Bernard; L Ferhat; F Dessi; G Charton; A Represa; Y Ben-Ari; M Khrestchatisky
Journal:  Eur J Neurosci       Date:  1999-02       Impact factor: 3.386

Review 4.  A crucial role for CD44 in inflammation.

Authors:  E Puré; C A Cuff
Journal:  Trends Mol Med       Date:  2001-05       Impact factor: 11.951

5.  Chromogranins in temporal lobe epilepsy.

Authors:  S Kandlhofer; B Hoertnagl; T Czech; C Baumgartner; H Maier; K Novak; G Sperk
Journal:  Epilepsia       Date:  2000       Impact factor: 5.864

6.  Kainate receptor activation induces mixed lineage kinase-mediated cellular signaling cascades via post-synaptic density protein 95.

Authors:  A Savinainen; E P Garcia; D Dorow; J Marshall; Y F Liu
Journal:  J Biol Chem       Date:  2001-01-10       Impact factor: 5.157

7.  Early induction of secretoneurin expression following kainic acid administration at convulsant doses in the rat and gerbil hippocampus.

Authors:  E Marti; J Blasi; I Ferrer
Journal:  Hippocampus       Date:  2002       Impact factor: 3.899

8.  Kainate-induced seizures alter protein composition and N-methyl-D-aspartate receptor function of rat forebrain postsynaptic densities.

Authors:  U Wyneken; K H Smalla; J J Marengo; D Soto; A de la Cerda; W Tischmeyer; R Grimm; T M Boeckers; G Wolf; F Orrego; E D Gundelfinger
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

9.  In vivo protein transduction: delivery of a biologically active protein into the mouse.

Authors:  S R Schwarze; A Ho; A Vocero-Akbani; S F Dowdy
Journal:  Science       Date:  1999-09-03       Impact factor: 47.728

10.  The neuroprotective effects of heat shock protein 27 overexpression in transgenic animals against kainate-induced seizures and hippocampal cell death.

Authors:  Mohammed T Akbar; Anna M C Lundberg; Ke Liu; Sharmili Vidyadaran; Kim E Wells; Hamid Dolatshad; Sarah Wynn; Dominic J Wells; David S Latchman; Jacqueline de Belleroche
Journal:  J Biol Chem       Date:  2003-03-13       Impact factor: 5.157

View more
  5 in total

1.  In Focus: Disease promoters during epileptogenesis.

Authors:  Thimmasettappa Thippeswamy
Journal:  J Neurosci Res       Date:  2019-08-21       Impact factor: 4.164

2.  Anti-Seizure and Neuronal Protective Effects of Irisin in Kainic Acid-Induced Chronic Epilepsy Model with Spontaneous Seizures.

Authors:  Jie Yu; Yao Cheng; Yaru Cui; Yujie Zhai; Wenshen Zhang; Mengdi Zhang; Wenyu Xin; Jia Liang; Xiaohong Pan; Qiaoyun Wang; Hongliu Sun
Journal:  Neurosci Bull       Date:  2022-07-12       Impact factor: 5.271

Review 3.  Inhibitors of Src Family Kinases, Inducible Nitric Oxide Synthase, and NADPH Oxidase as Potential CNS Drug Targets for Neurological Diseases.

Authors:  Meghan C Gage; Thimmasettappa Thippeswamy
Journal:  CNS Drugs       Date:  2021-01-30       Impact factor: 5.749

Review 4.  How to Find Candidate Drug-targets for Antiepileptogenic Therapy?

Authors:  Nian Yu; Xing-Jian Lin; Qing Di
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

5.  The Impacts of Surgery and Intracerebral Electrodes in C57BL/6J Mouse Kainate Model of Epileptogenesis: Seizure Threshold, Proteomics, and Cytokine Profiles.

Authors:  Karen Tse; Edward Beamer; Deborah Simpson; Robert J Beynon; Graeme J Sills; Thimmasettappa Thippeswamy
Journal:  Front Neurol       Date:  2021-07-12       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.